Engineering services firm G&S has lost a bid to shield emails about “the need to obtain legal advice” in a $270 million dispute with the operator of a NSW open-cut coal mine.
Online book retailer Booktopia has agreed to a $6 million penalty to resolve action brought by the consumer regulator alleging its refund policy was misleading.
Builder J Hutchinson and the CFMEU have been fined a combined $1.35 million for entered into an anti-competitive agreement to boycott an independent subcontractor at a construction site in Brisbane.
ASIC has told a judge AMP should face a $17.5 million penalty for deducting $356,000 from customers’ superannuation accounts for advice they never received, saying the wealth manager had shown “no real contrition” for its conduct.
The former owner of fitness franchise Zap Fitness has sued accounting firm Pitcher Partners, claiming it failed to properly advise on a troubled share buy-back scheme that spawned litigation the company paid $4.25 million to settle.
The state of Victoria can’t duck class action claims that failures in its hotel quarantine program caused businesses to suffer losses when stage three and four restrictions were put in place during the state’s second wave of COVID-19 cases in 2020.
Spirit Super and Palisade Investment Partners have withdrawn their $1.2 billion bid to acquire the Port of Geelong after the ACCC said the deal could substantially lessen competition in Victoria for the supply of bulk cargo port services.
A consolidated class action’s bid to include claims concerning dairy company a2 Milk’s disclosures to the New Zealand stock exchange is in doubt, despite broad agreement between the parties that the claims can be pursued in Victoria.
Mercedes-Benz will face a penalty in ACCC proceedings alleging the luxury car maker exposed consumers to serious injury or death by failing to comply with obligations under a compulsory recall of potentially deadly Takata airbags.
Two law firms that filed competing class actions against regenerative medicine company Mesoblast for allegedly misleading shareholders about its Remestemcel-L treatment for COVID-19 complications have agreed to join forces and sidestep a beauty parade.